1. Home
  2. SEED vs TCRT Comparison

SEED vs TCRT Comparison

Compare SEED & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Origin Agritech Limited

SEED

Origin Agritech Limited

SELL

Current Price

$0.69

Market Cap

8.5M

ML Signal

SELL

Logo Alaunos Therapeutics Inc.

TCRT

Alaunos Therapeutics Inc.

SELL

Current Price

$1.62

Market Cap

7.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
SEED
TCRT
Founded
1997
1998
Country
China
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.5M
7.8M
IPO Year
2005
2025

Fundamental Metrics

Financial Performance
Metric
SEED
TCRT
Price
$0.69
$1.62
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
15.3K
★ 1.6M
Earning Date
05-21-2026
11-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 24.66
EPS
★ N/A
N/A
Revenue
N/A
★ $15,900,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.65
$0.72
52 Week High
$1.73
$4.50

Technical Indicators

Market Signals
Indicator
SEED
TCRT
Relative Strength Index (RSI) 41.77 44.64
Support Level $0.67 $1.61
Resistance Level $1.07 $2.09
Average True Range (ATR) 0.05 0.17
MACD -0.00 -0.07
Stochastic Oscillator 19.11 10.16

Price Performance

Historical Comparison
SEED
TCRT

About SEED Origin Agritech Limited

Origin Agritech Ltd is a Chinese agricultural technology company operating in the PRC including seed research and development activities featured in crop seed breeding and genetic improvement. The company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.

About TCRT Alaunos Therapeutics Inc.

Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.

Share on Social Networks: